Stocks of the product already in Sri Lanka can still be sold, but
there will be no new imports of the talc, a popular healthcare
product across Sri Lanka and much of Asia, until J&J India, from
where Sri Lanka imports the product, provides fresh test results.
On Dec. 14, Reuters reported that the U.S. drugs and consumer
products group knew for decades that asbestos lurked in its Baby
Powder, leading to tests in several countries, including in India.
The report was based on thousands of pages of company memos,
internal reports, and other confidential documents.
J&J has described the Reuters story as "one-sided, false, and
inflammatory".
Kamal Jayasinghe, chief executive of Sri Lanka's National Medicine
Regulatory Authority (NMRA), which is part of the health ministry,
said it had informed the distributor, A.Baur & Co., that it would
require further tests for it to continue importing the powder.
"We have held their re-registration and informed the distributor to
submit quality reports from an accredited laboratory to ensure there
is no asbestos in their products,” Jayasinghe told Reuters.
The license for A.Baur & Co to import the product expired in
December, a second person at the NMRA said.
[to top of second column] |
Shalutha Perera, head of consumer for A.Baur, told Reuters the firm
has informed J&J in India of the suspension of the licensing
process.
"J&J India directly handles all the regulatory matters," he said.
Perera said the NMRA contacted A.Baur in December regarding new
asbestos testing.
A spokeswoman for J&J India declined to comment on the halt of
shipments to Sri Lanka but said the company "is in full compliance
with current Indian regulatory requirements for the manufacturing
and testing of our talc".
"We are fully cooperating with the Indian government and are
awaiting results from their testing," she added.
The spokeswoman said the product was routinely tested by both
suppliers and independent labs to ensure it is free of asbestos.
(Reporting by Shihar Aneez and Ranga Sirilal, additional reporting
and writing by Alasdair Pal; Editing by Martin Howell, Robert Birsel)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |